Loading clinical trials...
Loading clinical trials...
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X
Conditions
Interventions
ACE-083
Placebo
Locations
16
United States
University of California-Irvine
Orange, California, United States
University of Colorado
Aurora, Colorado, United States
University of Florida
Gainesville, Florida, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
University of Kansas Medical Center - Neurology Department
Kansas City, Kansas, United States
University of Minnesota, Neurology Department
Minneapolis, Minnesota, United States
Start Date
July 31, 2017
Primary Completion Date
March 11, 2020
Completion Date
March 11, 2020
Last Updated
September 26, 2022
NCT06794489
NCT01193088
NCT07049588
NCT06881979
NCT06203093
NCT05902351
Lead Sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions